|Day Low/High||7.61 / 8.17|
|52 Wk Low/High||3.26 / 9.12|
Remembering these 'rules of the road' is vital in this highly volatile space.
Here's two 'rules of the road' when investing in this highly volatile space.
The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.
Companies developing drugs for cancer, eye problems and pets -- offer untapped value.
Redhill has some promising drugs in its pipeline, and is well funded.